HGF/c-Met is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-20. Numbers and descriptions here follow the published literature rather than marketing material.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Following this Macdonald and Jim Aiken rigged a temperature probe to Alvin to measure the water temperature at the black smoker vents. This observed the highest temperatures then recorded at deep sea hydrothermal vents (380±30 °C). Analysis of black smoker material and the chimneys that fed them revealed that iron sulfide precipitates are the common minerals in the "smoke" and walls of the chimneys.
== Disease associations == The vast majority of patients with positive HLA-B27 will not develop an associated syndrome. The relationship between HLA-B27 and many diseases has not yet been fully elucidated. Though HLA-B27 is associated with a wide range of pathology, it does not appear to be the sole mediator in the development of disease. 90% of people with ankylosing spondylitis (AS) are HLA-B27 positive, although only a small fraction of people with HLA-B27 will develop AS. People who are HLA-B27 positive are more likely to experience early onset AS than HLA-B27 negative individuals. Research is uncovering other genes that predispose to AS and associated diseases, and there are potential environmental factors that may play a role in susceptible individuals. Approximately 40–50% of individuals with psoriatic arthritis have the HLA-B27 genotype. HLA-B27 is implicated in other types of seronegative spondyloarthropathy, such as reactive arthritis, acute anterior uveitis, iritis, Crohn's disease, and ulcerative colitis associated spondyloarthritis. The shared association with HLA-B27 leads to increased clustering of these diseases. HLA antigens have been studied in relation to autism.
Anatomy, In Our Time. BBC Radio 4. Melvyn Bragg with guests Ruth Richardson, Andrew Cunningham and Harold Ellis. "Anatomy of the Human Body". 20th edition. 1918. Henry Gray Parsons, Frederick Gymer (1911). "Anatomy" . Encyclopædia Britannica. Vol. 1 (11th ed.). pp. 920–943. Anatomia Collection: anatomical plates 1522 to 1867 (digitized books and images) Lyman, Henry Munson. The Book of Health (1898). Science History Institute Digital Collections Archived 2 February 2019 at the Wayback Machine. Gunther von Hagens True Anatomy for New Ways of Teaching.
Sources: en.wikipedia.org
==== Benign soft tissue neoplasms ==== Peripheral nerve sheath tumours: These most commonly are traumatic neuromas, a reactive response to trauma, neurilemmoma and neurofibroma which are large growing painless tumours usually found on the tongue. Neurofibroma may occur as a benign solitary lesion but can present as multiple lesions associated with (Von Reckllinghausen's Disease) neurofibromatosis. They can be preceded by café au lait pigmentation spots on the skin, and as they grow can become very disfiguring. Malignant change can occur in neurofibromatosis but very rarely in single lesion presentation. Mucosal neuromas can be associated with other conditions such as multiple endocrine neoplasia (MEN) syndrome and may precede thyroid cancer. Lipoma and fibrolipoma: These are tumours of adipose tissue, or fat, giving them a yellow appearance which varies according to fat content. They are usually soft, mobile, slow growing painless and occur mostly in middle age or the elderly. Granular cell tumour: These are also tumours arising from neural cells, though it was incorrectly thought to arise from muscle cells and therefore previously called granular cell myoblastoma. It also is slow growing large painless and occurs mostly in the tongue. Congenital epulis: These are also known as congenital granular cell tumours (but not related to granular cell tumours), and occur mostly on the upper gum, the maxillary alveolar ridge, of newborns, predominantly females. Rarely, they occur elsewhere, usually the tongue. They are usually self-resolving.
Whey protein concentrates (WPC) have typically low - though not absent - levels of fat and cholesterol. They also contain carbohydrates in the form of lactose. Whey protein isolates (WPI) are processed to remove fat and lactose, and as a result, WPI powders are typically over 90% protein by dry weight. Like WPC, WPI are mild and slightly milky in taste. Whey protein hydrolysates (WPH) are whey proteins that are predigested and partially hydrolyzed for the purpose of easier metabolizing. Their cost is generally higher than WPC and WPI. Highly hydrolysed whey may be less allergenic than other forms of whey, due to its smaller peptide chains. For this reason it is a common constituent in hypoallergenic baby milk formulas and medical foods. Native whey protein is extracted from skim milk, rather than being collected as a byproduct of cheese production. This type of whey does not contain glycomacropeptide, which is formed only after the addition of rennet. There is evidence that whey protein is more bio-available than casein or soy protein. Whey protein is commonly marketed as a dietary supplement, typically sold in powdered form for mixing into beverages. Whey protein is also often used as a thickener to improve texture and decrease syneresis in yogurt. Greek Yogurt, which increased in popularity in the early twenty‐first century, is typically high in protein.
26 April A firebase occupied by a unit of the 1st Brigade, 25th Infantry Division 20 km south of Tây Ninh was hit by 300 rounds of 82mm mortar and 107mm rocket fire and then attacked by an estimated two PAVN/VC battalions. The base was supported by artillery and helicopter and fixed wing gunships and 213 PAVN/VC were killed, six captured and 35 individual and 15 crew-served weapons captured.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.